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Abstract
Background A trade-off exists between building confi-
dence in health-economic (HE) decision models and the
use of scarce resources. We aimed to create a practical tool
providing model users with a structured view into the
validation status of HE decision models, to address this
trade-off.
Methods A Delphi panel was organized, and was com-
pleted by a workshop during an international conference.
The proposed tool was constructed iteratively based on
comments from, and the discussion amongst, panellists.
During the Delphi process, comments were solicited on the
importance and feasibility of possible validation techniques
for modellers, their relevance for decision makers, and the
overall structure and formulation in the tool.
Results The panel consisted of 47 experts in HE mod-
elling and HE decision making from various professional
and international backgrounds. In addition, 50 discussants
actively engaged in the discussion at the conference
workshop and returned 19 questionnaires with additional
comments. The final version consists of 13 items covering
all relevant aspects of HE decision models: the conceptual
model, the input data, the implemented software program,
and the model outcomes.
Conclusions Assessment of the Validation Status of
Health-Economic decision models (AdViSHE) is a vali-
dation-assessment tool in which model developers report in
a systematic way both on validation efforts performed and
on their outcomes. Subsequently, model users can establish
whether confidence in the model is justified or whether
additional validation efforts should be undertaken. In this
way, AdViSHE enhances transparency of the validation
status of HE models and supports efficient model
validation.Electronic supplementary material The online version of this
article (doi:10.1007/s40273-015-0327-2) contains supplementary
material, which is available to authorized users.
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Key Points
Model users can accept health-economic (HE)
decision models as valid without further
examination, thereby reducing model confidence, or
they can validate models themselves, implying
overlap with the validation efforts of the modelling
team. Existing modelling and validation guidelines
give little guidance in setting priorities for
validation, nor do they address the issue of
overlapping work by model developers and users.
Assessment of the Validation Status of Health-
Economic decision models (AdViSHE) allows
model developers to provide model users with
structured information regarding the validation status
of their HE decision model. Its main purpose is to
avoid some of the current overlap in validation
efforts and provide information on a list of priority
validation items, selected by a Delphi consensus
process. AdViSHE can be used to reproduce stated
results and guide complementary validation efforts,
which is expected to increase model users’
understanding of, and confidence in, the model and
its outcomes.
1 Introduction
The use of health-economic (HE) decision models can have
extensive consequences for payers, patients, and practi-
tioners alike. Since HE models have become a fixed part of
the modern decision making process in healthcare policy
[1], they should be validated before they are used. This is
commonly done by the modelling team and sometimes
extensively so. Since the cost of model validation can be
significant, both in time and money [2], model users, that
is, people using the outcomes of the model, such as reim-
bursement decision makers, could simply presume that the
models are valid without further examination. However,
this unquestioning acceptance may reduce the users’
overall confidence in the model, especially when the
modelling team has an economic interest in favourable
outcomes [3]. Model users therefore often validate models
themselves, leading to a possibly improved validation
status of the model but also an overlap of work between the
modelling team and model users.
We are thus presented with a trade-off between building
confidence in the model and the use of scarce resources.
Several guidelines and publications address model validity
and quality assessment, both for simulation models in
general [4–6] and for HE decision models in particular [3,
7–11]. However, they do not address the trade-off referred
to above or support modellers in setting validation priori-
ties. A prioritized list of validation efforts with the general
support of the research community may reduce possible
waste of resources while improving the general validation
status of HE models.
The aim of this study was therefore to create a practical
tool for model developers to fill in during or shortly after
model development. This tool provides model users with a
structured view into the validation status of the model,
according to a consensus on what good model validation
entails. The tool may also provide guidance towards
additional validation. This tool, called Assessment of the
Validation Status of Health-Economic decision models
(AdViSHE), may, for example, be part of dossiers sent to
the (national) decision maker when applying for reim-
bursement, or it may be appended to manuscripts on
modelling applications to support peer reviewers.
2 Methods
We defined validation as the act of evaluating whether a
model is a proper and sufficient representation of the sys-
tem it is intended to represent, in view of a specific
application. Here, ‘‘proper’’ means that the model is in
accordance with what is known about the system, and
‘‘sufficient’’ means that the results can serve as a solid basis
for decision making [12].
2.1 Initial List
A literature search generated an initial gross list of vali-
dation techniques. Explicit attention was given to the
inclusion of validation practices from outside the HE lit-
erature. Precise definitions were formulated to avoid con-
fusion between terms that may be used interchangeably in
daily practice.
2.2 Expert Input
In five e-mail rounds, HE experts commented on the initial
list and drafts of AdViSHE. The setup of these rounds was
based on the Delphi method, a structured communication
technique in which experts answer questions in two or
more rounds. The key element is that experts are encour-
aged to revise their earlier answers in light of the replies of
other members of their panel in order to reach consensus
[13–15]. The design of each round was not fixed before-
hand, but was based on the outcomes of the previous round.
A summary of the commentary from previous rounds was
provided and every participant was actively encouraged to
350 P. Vemer et al.
comment and provide suggestions for additions; all experts
were allowed to refine or change their opinion. Steps were
taken to include a wide variety of nationalities, work
environments, and expertise (Table 1). In between rounds,
new experts were approached to enhance international
diversity and to counter attrition.
Comments on an early draft of AdViSHE were solicited
from employees of Zorginstituut Nederland (the Dutch
Healthcare Institute), the primary advisory council for the
Dutch Ministry of Health regarding reimbursement. Zor-
ginstituut Nederland is representative of the field of policy
decision makers for whom AdViSHE might be useful.
A conference workshop was organized in Montreal,
Canada, where attendees discussed the first full draft of the
tool amongst themselves. Three of the authors (PV, GVV,
ICR) actively approached groups of discussants. All par-
ticipants were encouraged to comment using a question-
naire. All comments made during this workshop were
collected and incorporated in the final draft, which was sent
out to the Delphi panel in a final round of comments. It was
then edited for language, after which the project group
agreed on the final version of AdViSHE.
2.3 Case Studies
The applicability of AdViSHE was tested by applying it to
two case studies. Both were HE decision models in which
the study authors were involved. The first model was built
specifically for a Diagnostic Assessment Report commis-
sioned by the National Institute for Health Research Health
Technology Assessment Programme [16]. It was pro-
grammed in Microsoft Excel and assessed devices used to
assist with the diagnosis, management, and monitoring of
haemostasis disorders. The second one, with a multi-use
design and programmed in Wolfram Mathematica, is a
dynamic Dutch population model of chronic obstructive
pulmonary disease (COPD) progression [17]. AdViSHE
was filled in using knowledge of the models and their
development. The focus of this exercise was to identify any
problems with AdViSHE that a model developer might
encounter when applying it to a model.
3 Results
3.1 Building AdViSHE
The process of building AdViSHE is depicted in Fig. 1 and
additional information is given in the online supplementary
appendix (see electronic supplementary material, online
resource 1). The literature search yielded 35 validation
techniques [4–6, 9, 10, 18–22], which were then divided
Table 1 Source of contact information of health-economic experts
Source Number
of
experts
contacted
Personal network of the project team 129
Proposed replacements by invitees 10
Involved in the ISPOR-SMDM Good Modeling Practices
Task Force
31
Authors of the CHEERS statement [11] 6
Involved in the organizing committee of at least one of
the ISPOR conferences (International, European, Asia–
Pacific, and Latin America) between 2008 and 2014
140
Involved in the ISPOR regional chapters 100
Identified by other experts 19
Identified by biomedexperts.com as experts in
‘‘Economic Models’’ and/or ‘‘Markov Chains’’
35
CHEERS Consolidated Health Economic Evaluation Reporting
Standards, ISPOR International Society For Pharmacoeconomics and
Outcomes Research, SMDM Society for Medical Decision making
Fig. 1 Building the validation-assessment tool. Grey boxes display
work by the project team; white boxes display input from outside
sources. 1High non-response since the invitations were sent out to a
very wide range of people with the aim of selecting a suitable panel;
see Table 1. AdViSHE Assessment of the Validation Status of Health-
Economic decision models
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into groups covering all aspects of model validation
(Fig. 2). The Delphi panel ran from June 2013 until
September 2014. Background information on the HE
experts can be found in Table 2. The questions raised in
each round are presented in Fig. 3.
In the pilot and first rounds, every respondent could
comment on the full initial list, but was asked to at least
comment on the techniques grouped within two of the four
groups. Based on these rounds, nine techniques were
dropped from the initial list, since they were deemed
unimportant by the panel (Figs. 1, 3). Nine new techniques
proposed by panellists were included. Several items were
reformulated and combined.
To limit the burden, each panellist in the second and
third rounds received a subset of five validation techniques
to comment on, using a factorial design. The purpose was
to improve the definitions of the techniques, make neces-
sary clarifications, and hold an open discussion on the
usefulness of each item. Contrary to the first round, no
quantitative scoring was performed in these rounds. Based
on the first draft of AdViSHE built after the third round,
Zorginstituut Nederland suggested that the investigation of
outliers, which was excluded in a previous round due to an
average ‘‘importance’’ of 3.8 (below 4) was explicitly
mentioned in AdViSHE. The Delphi panel was asked to
comment on the amended first draft.
The conference workshop also discussed the first draft.
It was attended by approximately 50 participants; 19 filled-
in questionnaires were returned. Three workshop partici-
pants indicated that they were also members of the Delphi
panel.
The second draft was based on comments from the
fourth round and the workshop. Based on the workshop, a
final question was added, asking whether modellers have
performed any validation techniques not covered in
AdViSHE. The fifth Delphi round yielded no further sub-
stantial comments. The project team finalized the tool in
October 2014.
3.2 Final Version
The final version of AdViSHE consists of 13 questions
(Fig. 4). All questions are grouped to cover its various
aspects: the conceptual model, the input data, the imple-
mented software program, and the model outcomes
(Fig. 2). The tool is designed to be filled in by modellers to
Fig. 2 Typology of validation
techniques, based on [4]
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report in a structured way on the efforts performed to
improve the validation status of their HE decision model
and the outcomes of these efforts. The information required
to fill AdViSHE in is often available in other places, but is
not collected systematically.
3.3 Application to Case Studies
Filling in AdViSHE took a little over 1 h for each model.
No further issues with the formulation, structure or
usability of AdViSHE were found. It was noted that filling
in AdViSHE is best done during model development or
soon after.
4 Discussion
4.1 Application
The validation-assessment tool AdViSHE allows the
developers to provide the users with structured information
regarding the validation status of their HE decision model.
Its main purpose is to reduce the workload of model users
and avoid some of the current overlap in validation efforts,
thus saving resources. It does so by reporting which
validation efforts have been undertaken in a structured
way, and giving the results of these efforts. AdViSHE is
not intended to replace validation by model users, but
rather to reproduce stated results and guide complementary
validation efforts. By doing so, it is expected that the model
users will gain a greater understanding of, and confidence
in, the model and its outcomes.
AdViSHE can be particularly useful for decision makers
who have to evaluate a reimbursement dossier. In that
regard, the UK stands out internationally by providing
independent experts with an 8-week window to validate
HE decision models [23]; other jurisdictions have much
shorter timelines. In the Netherlands, for instance, Zor-
ginstituut Nederland has 3 weeks to comment on an HE
model and its outcomes before the reimbursement sub-
mission is send to the assessment committee (Weten-
schappelijke adviesraad, WAR) [24]. Since manufacturer
submissions rarely report on model validity, this often has
to be assessed independently. Due to time and money
constraints, model validation is sometimes insufficient to
establish confidence among users. To that end, inclusion of
AdViSHE in the reimbursement process could improve this
process, in particular, because it reports on validation cri-
teria based on consensus.
Participants in both the Delphi panel and the workshop
specifically asked for a short, quick-scan version.
AdViSHE could serve that purpose, using the answer
options ‘‘Yes’’ or ‘‘No’’ for each of the questions. This
checklist could be useful during the modelling process to
ascertain whether all important validation efforts have been
considered. It could also be useful during the process of
research dissemination, by accompanying academic arti-
cles or conference presentations.
AdViSHE gives neither a validity score, nor a threshold
for one. There are several reasons for this choice: a model
may receive a passing score and yet have a defect that
needs to be corrected; the subjective nature of this
approach tends to be hidden so the assessment appears to
be objective; scores may cause overconfidence in a model;
and scores can be used to argue that one model is better
than another [4]. Just as models must be tailored to an
application, validation efforts must be tailored to a specific
model. Therefore, no a priori ‘‘red flag’’ or ‘‘must do’’
labels have been defined for AdViSHE. A validation effort
that a model user deems indispensable for one application
may not be considered necessary for another.
4.2 Methodology
Themethodology used in this study is not a Delphi panel in a
strict sense. In a Delphi panel, a group of experts, usually
small, is given one specific question to answer. Each par-
ticipant is free to request additional data,which is then shared
Table 2 Background information of participants who answered
during at least one of the five Delphi rounds
Participant characteristics Number
(%)
Total number of individuals who answered in at least one
round
47 (100)
Geographical region [26]
Western Europe 28 (60)
Southern Europe 5 (11)
Northern Europe 4 (9)
Eastern Europe 3 (7)
North America 2 (4)
Central America 2 (4)
South America 1 (2)
Southern Asia 1 (2)
Australia and New Zealand 1 (2)
Field of work
Academics 25 (53)
Consulting 8 (17)
Pharmaceutical industry 8 (17)
Government, decision making 6 (13)
Number of responses
Provided comments three times or more 24 (50)
Provided comments twice 12 (26)
Provided comments once 12 (26)
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with the rest, along with their opinions [13–15]. In our study,
no single question could be posed in a meaningful way. We
therefore recruited a relatively large group of respondents,
each being asked to answer a subset of questions. Therebywe
mimicked the Delphi method as closely as possible. In some
rounds, we applied a factorial design to reduce the number of
questions presented to each respondent while keeping sev-
eral respondents for each question. The added value of
interaction between respondents that the Delphi method
provides was explicitly incorporated.
AdViSHE assumes that the modelling process is per-
formed with generally accepted modelling and reporting
techniques. This could mean that the model builders are
adhering to the International Society For
Pharmacoeconomics and Outcomes Research (ISPOR)—
Society for Medical Decision Making (SMDM) Modeling
Good Research Practices and to the Consolidated Health
Economic Evaluation Reporting Standards (CHEERS)
statement [1, 11]. AdViSHE does not evaluate the model
itself, nor the building process.
The intention of our study was to obtain a useful tool
that promotes the validation status of HE models by putting
resources to good use and providing a consensus on the
reporting on this effort. Close to 100 people have actively
participated and discussed (parts of) AdViSHE. This large,
diverse group of respondents was one of the biggest
strengths of our study. In our Delphi panel, we have rep-
resentatives of many different geographical regions and
Fig. 3 HE expert questions.
AdViSHE Assessment of the
Validation Status of Health-
Economic decision models, HE
health-economic. 1 ISPOR
International Society For
Pharmacoeconomics and
Outcomes Research
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working fields relevant to HE modelling. Their input gave
useful information both of a qualitative and a quantitative
nature, and our design allowed for the suggestion of other
methods not yet included in the list. The workload of the
Delphi panel was relatively low due to the factorial design
in the second and third rounds. Although this meant that
participants did not comment on all validation techniques,
it did keep participants interested.
One of the limitations of our study was that the time
path to consensus was more than a year and it was labour
intensive to filter all information after each round. Since
this filtering of information was to some extent subjective,
there is no complete certainty that consensus was unani-
mous, although the reactions to the full drafts were posi-
tive. A final limitation of the study is that the original
search for validation techniques was not based on a
AdViSHE
Assessment of the Validation Status of
Health-Economic decision models
AdViSHE contains 13 items that modellers can complete to report on the efforts 
performed to improve the validation status of their health-economic (HE) decision model. 
The tool is not intended to replace validation by model users but rather to inform the 
direction of validation efforts and to provide a baseline for replication of the results. In 
addition to using it after a model is finished, AdViSHE can be used to guide validation 
efforts during the modelling process.
The modellers are asked to comment on the validation efforts performed while building 
the underlying HE decision model and afterwards. Many of the items can be answered 
simply by referring to the model documentation. AdViSHE is divided into five parts, each 
covering an aspect of validation:
- Part A: Validation of the conceptual model (2 questions)
- Part B: Input data validation (2 questions)
- Part C: Validation of the computerized model (4 questions)
- Part D: Operational validation (4 questions)
- Part E: Other validation techniques (1 question)
No final validation score is calculated, as the assessment of the answers and the overall 
validation effort is left to the model users. It is assumed that the model has been built 
according to prevailing modelling and reporting guidelines. For instance, the model 
builders would presumably adhere to the ISPOR-SMDM1 Modeling Good Research 
Practices (Caro et al., 2010) and/or CHEERS1 Statement (Husereau et al., 2013). Some 
questions may not be applicable to a particular model. If this is the case, the model 
builder should take the opt-out option and provide a justification of why this item is not 
deemed applicable.
Part A: Validation of the conceptual model (2 questions)
Part A discusses techniques for validating the conceptual model. A conceptual model 
describes the underlying system (e.g., progression of disease) using a mathematical, 
logical, verbal, or graphical representation. Please indicate where the conceptual model 
and its underlying assumptions are described and justified.
A1/ Face validity testing (conceptual model): Have experts been asked to judge 
the appropriateness of the conceptual model?
If yes, please provide information on the following aspects: 
- Who are these experts?
- What is your justification for considering them experts?
- To what extent do they agree that the conceptual model is appropriate?
If no, please indicate why not.
Aspects to judge include: appropriateness to represent the underlying clinical process/disease (disease stages, 
physiological processes, etc.); and appropriateness for economic evaluation (comparators, perspective, costs 
covered, etc.).
A2/ Cross validity testing (conceptual model): Has this model been compared to 
other conceptual models found in the literature or clinical textbooks?
If yes, please indicate where this comparison is reported.
If no, please indicate why not.
Fig. 4 AdViSHE: Assessment
of the Validation Status of
Health-Economic decision
models. 1 ISPOR
International Society For
Pharmacoeconomics and
Outcomes Research, SMDM
Society for Medical Decision
making, CHEERS Consolidated
Health Economic Evaluation
Reporting Standards
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systematic review of the literature. We started with a list of
ten guidelines from inside and outside the HE field and
listed all techniques mentioned in these guidelines. By
allowing the Delphi panel and the workshop participants to
add techniques they considered useful, we have used an
alternative approach to sufficiently guarantee inclusion of
all relevant techniques on the list of items considered.
4.3 Comparison to Other Tools
Several tools that have been published in the past few years
deal with the quality assessment of HE decision models [3,
8]. Others deal with the quality of reporting of HE decision
models [7, 9, 11]. Only one of these recent tools refers
explicitly to validation, namely that of Caro et al., which
briefly discusses validation as a part of the tool’s overall
‘‘credibility’’ [3]. The Drummond and Jefferson [7] and
Consensus on Health Economic Criteria (CHEC) [8]
checklists, and the Philips framework [9] were intended to be
filled in bymodellers to help them in the model development
process, although it is implied that model users can fill them
into evaluate models [7, 9]. TheCHEERS checklist was built
to be used by both model developers and model users, in
particular, editors and peer reviewers evaluating publication
Part B: Input data validation (2 questions)
Part B discusses techniques to validate the data serving as input in the model. These 
techniques are applicable to all types of models commonly used in HE modelling.
Please indicate where the description and justification of the following aspects are given:
- search strategy;
- data sources, including descriptive statistics;
- reasons for inclusion of these data sources;
- reasons for exclusion of other available data sources;
- assumptions that have been made to assign values to parameters for which no data was available; 
- distributions and parameters to represent uncertainty; 
- data adjustments: mathematical transformations (e.g., logarithms, squares); treatment of outliers; 
treatment of missing data; data synthesis (indirect treatment comparison, network meta-analysis); 
calibration; etc.
B1/ Face validity testing (input data): Have experts been asked to judge the 
appropriateness of the input data?
If yes, please provide information on the following aspects: 
- Who are these experts?
- What is your justification for considering them experts?
- To what extent do they agree that appropriate data have been used?
If no, please indicate why not.
Aspects to judge may include but are not limited to: potential for bias; generalizability to the target population; 
availability of alternative data sources; any adjustments made to the data.
B2/ Model fit testing: When input parameters are based on regression models, have 
statistical tests been performed?
If yes, please indicate where the description, the justification and the outcomes of these tests are reported.
If no, please indicate why not.
Examples of regression models include but are not limited to: disease progression based on survival curves; 
risk profiles using regression analysis on a cohort; local cost estimates based on multi-level models; meta-
regression; quality-of-life weights estimated using discrete choice analysis; mapping of disease-specific quality-
of-life weights to utility values.
Examples of tests include but are not limited to: comparing model fit parameters (R2, Akaike information 
criterion (AIC), Bayesian information criterion (BIC)); comparing alternative model specifications (covariates, 
distributional assumptions); comparing alternative distributions for survival curves (Weibull, lognormal, logit); 
testing the numerical stability of the outcomes (sufficient number of iterations); testing the convergence of the 
regression model; visually testing model fit and/or regression residuals.
Part C: Validation of the computerized model (4 questions)
Part C discusses various techniques for validating the model as it is implemented in a 
software program. If there are any differences between the conceptual model (Part A) 
and the final computerized model, please indicate where these differences are reported 
and justified.
Fig. 4 continued
356 P. Vemer et al.
potential of economic evaluations [11]. The checklist by
Caro et al. was specially built to be filled in by model users
[3]. Using these tools for their intended purpose will hence
often add to the workload of model users and may overlap
with work already done by the developers. In addition to the
mentioned checklists, AdViSHEwas specifically intended to
be filled in by modellers, while its outcome is immediately
useful to model users.
There are also several tools that deal with model vali-
dation for simulation models in general [4–6]. However,
these present ideals rather than a priority list of feasible
acceptability criteria. In addition, most recommendations
are necessarily general and not geared towards validating
HE models [4–6]. The limited number of validation tech-
niques in AdViSHE is a consensus between what is feasible
and what is necessary in HE modelling. For specific
C1/ External review: Has the computerized model been examined by modelling 
experts?
If yes, please provide information on the following aspects:
- Who are these experts?
- What is your justification for considering them experts?
- Can these experts be qualified as independent?
- Please indicate where the results of this review are reported, including a discussion of any unresolved 
issues.
If no, please indicate why not.
Aspects to judge may include but are not limited to: absence of apparent bugs; logical code structure 
optimized for speed and accuracy; appropriate translation of the conceptual model.
C2/ Extreme value testing: Has the model been run for specific, extreme sets of 
parameter values in order to detect any coding errors?
If yes, please indicate where these tests and their outcomes are reported.
If no, please indicate why not.
Examples include but are not limited to: zero and extremely high (background) mortality; extremely beneficial, 
extremely detrimental, or no treatment effect; zero or extremely high treatment or healthcare costs.
C3/ Testing of traces: Have patients been tracked through the model to determine 
whether its logic is correct?
If yes, please indicate where these tests and their outcomes are reported.
If no, please indicate why not.
In cohort models, this would involve listing the number of patients in each disease stage at one, several, or all 
time points (e.g., Markov traces). In individual patient simulation models, this would involve following several 
patients throughout their natural disease progression.
C4/ Unit testing: Have individual sub-modules of the computerized model been tested?
If yes, please provide information on the following aspects: 
- Was a protocol that describes the tests, criteria, and acceptance norms defined beforehand?
- Please indicate where these tests and their outcomes are reported.
If no, please indicate why not.
Examples include but are not limited to: turning sub-modules of the program on and off; altering global 
parameters; testing messages (e.g., warning against illegal or illogical inputs), drop-down menus, named 
areas, switches, labelling, formulas and macros; removing redundant elements.
Part D: Operational validation (4 questions)
Part D discusses techniques used to validate the model outcomes.
D1/ Face validity testing (model outcomes): Have experts been asked to judge the 
appropriateness of the model outcomes?
If yes, please provide information on the following aspects: 
- Who are these experts?
- What is your justification for considering them experts?
- To what extent did they conclude that the model outcomes are reasonable?
If no, please indicate why not.
Outcomes may include but are not limited to: (quality-adjusted) life years; deaths; hospitalizations; total 
costs.
Fig. 4 continued
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D2/ Cross validation testing (model outcomes): Have the model outcomes been 
compared to the outcomes of other models that address similar problems?
If yes, please provide information on the following aspects: 
- Are these comparisons based on published outcomes only, or did you have access to the alternative model?
- Can the differences in outcomes between your model and other models be explained?
- Please indicate where this comparison is reported, including a discussion of the comparability with your 
model.
If no, please indicate why not.
Other models may include models that describe the same disease, the same intervention, and/or the same 
population.
D3/ Validation against outcomes using alternative input data: Have the model 
outcomes been compared to the outcomes obtained when using alternative input data?
If yes, please indicate where these tests and their outcomes are reported.
If no, please indicate why not.
Alternative input data can be obtained by using different literature sources or datasets, but can also be 
constructed by splitting the original data set in two parts, and using one part to calculate the model outcomes 
and the other part to validate against.
D4/ Validation against empirical data: Have the model outcomes been compared to 
empirical data?
If yes, please provide information on the following aspects:
- Are these comparisons based on summary statistics, or patient-level datasets?
- Have you been able to explain any difference between the model outcomes and empirical data?
- Please indicate where this comparison is reported.
If no, please indicate why not.
D4.A/ Comparison against the data sources on which the model is based (dependent validation).
D4.B/ Comparison against a data source that was not used to build the model (independent validation).
Part E: Other validation techniques (1 question)
E1/ Other validation techniques: Have any other validation techniques been 
performed?
If yes, indicate where the application and outcomes are reported, or else provide a short summary here.
Examples of other validation techniques: structured “walk-throughs” (guiding others through the conceptual 
model or computerized program step-by-step); naïve benchmarking (“back-of-the-envelope” calculations); 
heterogeneity tests; double programming (two model developers program components independently and/or 
the model is programmed in two different software packages to determine if the same results are obtained).
Fig. 4 continued
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applications, additional items may of course be very
important, which can be reported in the last part of
AdViSHE. As a priority list, AdViSHE thus supplements
existing tools and guidelines with different purposes.
Despite efforts to make the evidence as objective as
possible, the judgment of model validity (and confidence)
will ultimately be subjective. It is therefore of paramount
importance that model users can make their own assess-
ment. AdViSHE makes this possible in an efficient way: it
asks not only which validation aspects were tested but also
how they were tested and where the outcomes are reported.
Other tools just provide general suggestions for which
aspects should be discussed. The exception is the CHEERS
checklist, which also asks specifically where certain items
are reported [3, 7–9, 11].
4.4 Terminology
There is little if any consensus on terminology in the val-
idation literature [25], even in the field of HE. The problem
of ambiguity is exacerbated by the different meanings of
the same terms in computer science and psychometrics. For
example, conceptual model validation is sometimes called
content validity [9, 18], but in psychometrics, this term
indicates whether a measure represents all facets of a given
social construct. Computerized model validity is some-
times called verification, internal validity, internal consis-
tency, technical validity, and debugging; moreover, all of
these terms have additional and divergent meanings.
Notably, internal validity was interpreted differently by
several members of the Delphi panel.
In AdViSHE, we have attempted to steer clear of termi-
nology that may be considered confusing.We present a lucid
overview of possible techniques, with clear definitions, to be
used in the validation of HE decision models. This explains
the discrepancy between our terms and the classification of
validation types by the recent ISPOR-SMDM Modeling
Good Research Practices Task Force [10].
5 Conclusion
A validation-assessment tool for HE models called
Assessment of the Validation Status of Health-Economic
decision models (AdViSHE) has been developed to address
the trade-off that model users potentially experience,
between a loss of confidence resulting from lacking or
unreported validation efforts, and an inefficient use of
resources resulting from overlapping validation efforts by
the modelling team and model users. In addition, it presents
a certain consensus among model users and model devel-
opers on what is good validation. The tool is tailored for
the validation of HE models through the involvement of a
large group of HE experts, coming from many backgrounds
and countries. In AdViSHE, model developers comment on
the validation efforts performed while building the under-
lying HE decision model. This information can subse-
quently be applied by model users, such as people involved
in decision making or peer reviewers, to establish whether
confidence in the model is warranted or additional valida-
tion efforts should be undertaken. The tool thus reduces the
overlap between the validation efforts of model developers
and those of model users without leading to a loss of
confidence in the model or its outcomes.
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